Matthew Sender
Director LigaChem Biosciences
Matthew has 13 years of experience in industry across medicinal chemistry, chemical biology, and ADCs. LigaChem Biosciences for the last two years after 11 with GSK. Matthew has a passion for chemistry, biology and medicine are united in the design and development of ADCs.
Seminars
Tuesday 9th March 2027
LCB43: A Next-Generation Beta-Glucuronide BCMA ADC for the Treatment of Multiple Myeloma
10:45 am
- Belantamab Mafodotin is a great ADC held back by ocular toxicity
- Sharing clinical evidence of less ocular toxicity
- Addressing the key limitation of blenrep using LCB43, a next-generation ADC
